Grifols : Covid-19: Bane or boon?
>Covid's negative impact should continue to be felt in H2 while related long-term opportunities remain somewhat remote - Production has not been materially impacted by the pandemic as the plasma industry has been designated an essential business, allowing Grifols and Kedrion to ensure uninterrupted production. On the demand side, sales of some proteins were affected by the healthcare industry's overwhelming focus on fighting the pandemic, but this was temporary. Cov...Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.